Table 3 Quality assessment of eligible studies
Study | Inclusion and exclusion criteria | Prospective/Retrospective | Patient characteristics | Tumor characteristics | LNR measurements | Endpoint | Follow-up period | Patients unavailable for statistical analysis | Quality scale |
|---|---|---|---|---|---|---|---|---|---|
Choi 2019 [12] | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 5 |
Ye 2018 [22] | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |
Lo 2017 [15] | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 5 |
Suzuki 2016 [21] | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 6 |
Imre 2016 [19] | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 6 |
Ryu 2015 [16] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
Kunzel 2015 [20] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
Joo 2015 [14] | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 6 |
Hua 2015 [13] | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 4 |
Wang 2014 [28] | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 4 |
Yu 2013 [29] | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 5 |
Wang 2013 [27] | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 6 |
Grasl 2019 [18] | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 6 |